OBJECTIVE: To determine the rate of growth in vestibular schwannomas and the rate of hearing decline in neurofibromatosis type 2 (NF2) patients not undergoing active treatment STUDY DESIGN: Prospective study. SETTING: Data were collected at 10 NF2 centers, including hospital-based, academic, and tertiary care centers. PATIENTS: 120 NF2 patients with 200 vestibular schwannomas. OUTCOME MEASURES: Hearing decline, defined as a decrease in word recognition score outside the 95% critical difference compared with baseline, and radiographic progression, defined as a 20% or greater increase in tumor volume compared with baseline. RESULTS: During a total of 313.4 patient-years of follow-up, the rate of hearing decline was 5% at 1 year, 13% at 2 years, and 16% at 3 years; the rate of tumor progression was 31% at 1 year, 64% at 2 years, and 79% at 3 years. For this cohort, the median time to tumor progression (14 mo) was significantly shorter than the median time to hearing decline (62.0 mo). CONCLUSION: These data provide potentially useful information for the design of clinical trials for NF2 vestibular schwannoma.
OBJECTIVE: To determine the rate of growth in vestibular schwannomas and the rate of hearing decline in neurofibromatosis type 2 (NF2) patients not undergoing active treatment STUDY DESIGN: Prospective study. SETTING: Data were collected at 10 NF2 centers, including hospital-based, academic, and tertiary care centers. PATIENTS: 120 NF2patients with 200 vestibular schwannomas. OUTCOME MEASURES: Hearing decline, defined as a decrease in word recognition score outside the 95% critical difference compared with baseline, and radiographic progression, defined as a 20% or greater increase in tumor volume compared with baseline. RESULTS: During a total of 313.4 patient-years of follow-up, the rate of hearing decline was 5% at 1 year, 13% at 2 years, and 16% at 3 years; the rate of tumor progression was 31% at 1 year, 64% at 2 years, and 79% at 3 years. For this cohort, the median time to tumor progression (14 mo) was significantly shorter than the median time to hearing decline (62.0 mo). CONCLUSION: These data provide potentially useful information for the design of clinical trials for NF2vestibular schwannoma.
Authors: Yingchao Zhao; Pinan Liu; Na Zhang; Jie Chen; Lukas D Landegger; Limeng Wu; Fu Zhao; Yanxia Zhao; Yanling Zhang; Jing Zhang; Takeshi Fujita; Anat Stemmer-Rachamimov; Gino B Ferraro; Hao Liu; Alona Muzikansky; Scott R Plotkin; Konstantina M Stankovic; Rakesh K Jain; Lei Xu Journal: Proc Natl Acad Sci U S A Date: 2018-02-09 Impact factor: 11.205
Authors: Jaishri O Blakeley; Xiaobu Ye; Dan G Duda; Chris F Halpin; Amanda L Bergner; Alona Muzikansky; Vanessa L Merker; Elizabeth R Gerstner; Laura M Fayad; Shivani Ahlawat; Michael A Jacobs; Rakesh K Jain; Christopher Zalewski; Eva Dombi; Brigitte C Widemann; Scott R Plotkin Journal: J Clin Oncol Date: 2016-03-14 Impact factor: 44.544
Authors: Victoria Huang; Amanda L Bergner; Chris Halpin; Vanessa L Merker; Monica R Sheridan; Brigitte C Widemann; Jaishri O Blakeley; Scott R Plotkin Journal: Otol Neurotol Date: 2018-06 Impact factor: 2.311
Authors: Scott R Plotkin; Simone L Ardern-Holmes; Fred G Barker; Jaishri O Blakeley; D Gareth Evans; Rosalie E Ferner; Tessa A Hadlock; Chris Halpin Journal: Neurology Date: 2013-11-19 Impact factor: 9.910